NO974767L - Anvendelse av glianeurotrof faktor (GDNF) til behandling av hörselsforstyrrelser - Google Patents

Anvendelse av glianeurotrof faktor (GDNF) til behandling av hörselsforstyrrelser

Info

Publication number
NO974767L
NO974767L NO974767A NO974767A NO974767L NO 974767 L NO974767 L NO 974767L NO 974767 A NO974767 A NO 974767A NO 974767 A NO974767 A NO 974767A NO 974767 L NO974767 L NO 974767L
Authority
NO
Norway
Prior art keywords
gdnf
neurotrophic factor
treatment
hearing disorders
glial
Prior art date
Application number
NO974767A
Other languages
English (en)
Norwegian (no)
Other versions
NO974767D0 (no
Inventor
Ella Magal
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/606,176 external-priority patent/US5837681A/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO974767D0 publication Critical patent/NO974767D0/no
Publication of NO974767L publication Critical patent/NO974767L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NO974767A 1996-02-23 1997-10-15 Anvendelse av glianeurotrof faktor (GDNF) til behandling av hörselsforstyrrelser NO974767L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/606,176 US5837681A (en) 1996-02-23 1996-02-23 Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US08/710,219 US5929041A (en) 1996-02-23 1996-09-13 Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
PCT/US1997/002677 WO1997030722A1 (en) 1996-02-23 1997-02-14 Use of glial neurotrophic factor (gdnf) for treatment of hearing disorders

Publications (2)

Publication Number Publication Date
NO974767D0 NO974767D0 (no) 1997-10-15
NO974767L true NO974767L (no) 1997-12-22

Family

ID=27085161

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974767A NO974767L (no) 1996-02-23 1997-10-15 Anvendelse av glianeurotrof faktor (GDNF) til behandling av hörselsforstyrrelser

Country Status (21)

Country Link
US (1) US5929041A (da)
EP (1) EP0822829B1 (da)
JP (1) JP4028598B2 (da)
KR (1) KR100271247B1 (da)
CN (1) CN1130221C (da)
AT (1) ATE211392T1 (da)
AU (1) AU691443B2 (da)
CA (1) CA2217565C (da)
CZ (1) CZ322797A3 (da)
DE (1) DE69709458T2 (da)
DK (1) DK0822829T3 (da)
EA (1) EA199700225A1 (da)
ES (1) ES2170938T3 (da)
HU (1) HU223999B1 (da)
IL (1) IL121790A (da)
MX (1) MX9707669A (da)
NO (1) NO974767L (da)
NZ (1) NZ328918A (da)
PT (1) PT822829E (da)
SK (1) SK138697A3 (da)
WO (1) WO1997030722A1 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
WO1998020889A1 (en) * 1996-11-15 1998-05-22 Creative Biomolecules Inc Morphogen peptide-induced regeneration of sense perceptory tissues
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
EP1304119A3 (en) * 1997-07-30 2004-01-21 Amgen Inc. Method for preventing and treating hearing loss using a neurturin protein product
US6177434B1 (en) * 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US7236888B2 (en) * 1998-03-06 2007-06-26 The Regents Of The University Of California Method to measure the activation state of signaling pathways in cells
US6309410B1 (en) 1998-08-26 2001-10-30 Advanced Bionics Corporation Cochlear electrode with drug delivery channel and method of making same
US6304787B1 (en) 1998-08-26 2001-10-16 Advanced Bionics Corporation Cochlear electrode array having current-focusing and tissue-treating features
CN1329034C (zh) 1998-09-25 2007-08-01 赛福伦公司 预防/治疗感觉毛细胞和耳蜗神经元损伤的药物
US7053200B1 (en) 1999-06-01 2006-05-30 Baylor College Of Medicine Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation
EP1471926B8 (en) * 1999-06-01 2011-09-21 Baylor College Of Medicine Compositions and methods for the therapeutic use of an atonal-associated sequence
DK1223966T3 (da) * 1999-10-29 2003-08-18 Bioph Biotech Entw Pharm Gmbh Anvendelse af GDNF til behandling af hornhindedefekter
US6551575B1 (en) * 1999-12-02 2003-04-22 Neurosciences Research Foundation, Inc. Methods for identifying compounds for motion sickness, vertigo and other disorders related to balance and the perception of gravity
DE10025152A1 (de) * 2000-05-23 2001-12-06 Marlies Knipper Neurotrophin stimulierende Substanzen, insbesondere Thyroidhormon (T3) oder Schilddrüsenhormon stimulierende Substanzen, für die therapeutische Behandlung von lärm-und altersbedingter Schwerhörigkeit
AUPR148400A0 (en) * 2000-11-14 2000-12-07 Cochlear Limited Apparatus for delivery of pharmaceuticals to the cochlea
US9089450B2 (en) * 2000-11-14 2015-07-28 Cochlear Limited Implantatable component having an accessible lumen and a drug release capsule for introduction into same
WO2004096256A1 (en) * 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
US20030050273A1 (en) * 2001-08-29 2003-03-13 Keiya Ozawa Compositions and methods for treating neurodegenerative diseases
AUPR879201A0 (en) * 2001-11-09 2001-12-06 Cochlear Limited Subthreshold stimulation of a cochlea
AUPS081502A0 (en) * 2002-02-28 2002-03-21 Cochlear Limited Connector for drug delivery system
JP4533144B2 (ja) * 2002-10-02 2010-09-01 アンジェスＭｇ株式会社 聴覚機能障害用医薬
WO2004050056A1 (en) * 2002-11-29 2004-06-17 Cochlear Limited Cochlear implant drug delivery device
US20040166091A1 (en) * 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
US8309057B2 (en) * 2005-06-10 2012-11-13 The Invention Science Fund I, Llc Methods for elevating neurotrophic agents
US8133215B2 (en) * 2007-08-13 2012-03-13 Cochlear Limited Independently-manufactured drug delivery module and corresponding receptacle in an implantable medical device
US8271101B2 (en) * 2007-08-29 2012-09-18 Advanced Bionics Modular drug delivery system for minimizing trauma during and after insertion of a cochlear lead
WO2009029866A2 (en) * 2007-08-29 2009-03-05 Advanced Bionics, Llc Minimizing trauma during and after insertion of a cochlear lead
CN104491864A (zh) 2008-04-21 2015-04-08 奥德纳米有限公司 用于治疗耳部疾病和病况的耳用调配物及方法
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
US8617097B2 (en) 2010-05-24 2013-12-31 Cochlear Limited Drug-delivery accessory for an implantable medical device
US8920855B1 (en) 2012-10-30 2014-12-30 Setem Hemth, Inc Methods of topically treating tinnitus and related disorders
EP2968462B1 (en) 2013-03-15 2020-12-23 The Jackson Laboratory Methods for promoting wound healing and hair growth
JP2017508793A (ja) * 2014-03-05 2017-03-30 シュワルツ、ローレンス エム.SCHWARTZ, Lawrence M. 感覚細胞を保護するための方法及び組成物
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
US10975152B2 (en) * 2016-05-03 2021-04-13 The Scripps Research Institute TrkB agonist antibodies and methods for treating an ocular degenerative disorder characterized by degeneration of retinal ganglion cells (RGCs)
EP3538560A4 (en) 2016-11-10 2020-06-17 Keros Therapeutics, Inc. GDNF FUSION POLYPEPTIDES AND METHODS OF USE
EP3406259A1 (en) * 2017-05-24 2018-11-28 Dompé farmaceutici S.p.A. Neurotrophins for use in the treatment of hearing loss
CA3087574A1 (en) * 2018-01-09 2019-07-18 Otonomy, Inc. Growth factor otic formulations
CN112920998B (zh) * 2021-02-05 2022-06-14 复旦大学附属眼耳鼻喉科医院 一种成年鼠耳蜗体培养体系的建立方法及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5106627A (en) * 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
WO1990006952A1 (en) * 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
WO1991010470A1 (en) * 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
EP1243652A3 (en) * 1991-09-20 2003-03-26 Amgen Inc., Glial derived neurotrophic factor
DK0802800T3 (da) * 1993-08-12 2002-10-07 Neurotech Sa Biokompatible immunoisolatoriske kapsler indeholdende genetisk ændrede celler for levering af biologisk aktive molekyler
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US5658785A (en) * 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods

Also Published As

Publication number Publication date
WO1997030722A1 (en) 1997-08-28
EP0822829A1 (en) 1998-02-11
NZ328918A (en) 1999-08-30
CA2217565A1 (en) 1997-08-28
KR19980703748A (ko) 1998-12-05
KR100271247B1 (ko) 2000-11-01
AU2277997A (en) 1997-09-10
JP4028598B2 (ja) 2007-12-26
EA199700225A1 (ru) 1998-04-30
SK138697A3 (en) 1998-02-04
CZ322797A3 (cs) 1998-01-14
CA2217565C (en) 2002-04-16
HUP9901758A2 (hu) 1999-08-30
CN1130221C (zh) 2003-12-10
ES2170938T3 (es) 2002-08-16
PT822829E (pt) 2002-06-28
IL121790A0 (en) 1998-02-22
HUP9901758A3 (en) 2001-10-29
NO974767D0 (no) 1997-10-15
DE69709458D1 (de) 2002-02-07
EP0822829B1 (en) 2002-01-02
MX9707669A (es) 1997-11-29
DK0822829T3 (da) 2002-04-02
AU691443B2 (en) 1998-05-14
IL121790A (en) 2002-08-14
JPH11504351A (ja) 1999-04-20
US5929041A (en) 1999-07-27
DE69709458T2 (de) 2002-08-29
HU223999B1 (hu) 2005-04-28
ATE211392T1 (de) 2002-01-15
CN1181704A (zh) 1998-05-13

Similar Documents

Publication Publication Date Title
NO974767L (no) Anvendelse av glianeurotrof faktor (GDNF) til behandling av hörselsforstyrrelser
DK1005358T3 (da) Anvendelse af et neurturinprotein-produkt til forebyggelse og behandling af hørenedsættelse
NO982276L (no) Fremgangsmöte for behandling av retinal ganglioncelleskade under anvendelse av proteinprodukt av gliacellelinjeavledet neurotrof faktor (GDNF)
EP0254032A3 (en) Neutral metalloendopeptidase inhibitors in the treatment of hypertension
WO2001037782A3 (en) Method and composition for the treatment of scars
ATE281840T1 (de) Behandlung von diarrhoe
WO2004031363A3 (en) Room temperature stable competent cells
NO992400L (no) Nye substituerte pyrazolderivater
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
DE69521620T2 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
ATE421329T1 (de) Verwendung von aplidine zur behandlung von kardiovaskulären erkrankungen
AU2838101A (en) Use of melatonin for treating androgenetic and diffuse alopecia
ATE318610T1 (de) Orale zusammensetzungen zur behandlung von kopfhauterkrankungen
WO1998020029A3 (en) Hnf3-delta compositions
NO20013493D0 (no) Anvendelse av neurotrofin samt analoger derav ved behandling av gastrointestinale hypomotilitetslidelser
WO1999041364A3 (en) Compositions and methods for wound healing
CA2249666A1 (en) Macrophage stimulating protein for the treatment of gastrointestinal disorders
NO984760L (no) Anvendelse av en osmolytt ved behandling av effekter forÕrsaket av en infeksjon, en inflammasjon eller en immundysfunksjon
CA2353527A1 (en) Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
NO20012423D0 (no) Antikonvulsjonsmiddelderivater som er nyttige ved behandling av posttraumatiske stresslidelser
BG101125A (en) Low molecular biologically active substance of yeasts and method for its preparation
WO2000061125A3 (fr) L'osanetant dans le traitement des troubles de l'humeur
EP1085093A3 (en) Genes and polynucleotides associated with ultraviolet radiation-mediated skin damage and uses thereof
NZ334762A (en) Human DNase I variants having binding affinity to actin
ATE338768T1 (de) Muc-1 derivate und deren verwendung zur behandlung von krebsassoziierter muc-1 mucin induzierter immunosuppression